Amylin Pharmaceuticals, Inc and Takeda Pharmaceutical Company Limited have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase-2 development for treatment of obesity.
The details can be read here.
No comments:
Post a Comment